Keene & Associates Inc. Has $337,000 Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Keene & Associates Inc. boosted its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 5.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 22,945 shares of the company’s stock after purchasing an additional 1,240 shares during the quarter. Keene & Associates Inc.’s holdings in Elanco Animal Health were worth $337,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Benjamin F. Edwards & Company Inc. grew its holdings in shares of Elanco Animal Health by 337.7% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock valued at $26,000 after buying an additional 1,361 shares during the last quarter. ORG Wealth Partners LLC acquired a new position in shares of Elanco Animal Health during the third quarter valued at about $29,000. nVerses Capital LLC acquired a new position in shares of Elanco Animal Health during the second quarter valued at about $32,000. ORG Partners LLC purchased a new position in Elanco Animal Health during the second quarter worth about $31,000. Finally, Quarry LP purchased a new position in Elanco Animal Health during the second quarter worth about $40,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Price Performance

NYSE:ELAN opened at $12.51 on Thursday. The firm has a market capitalization of $6.18 billion, a price-to-earnings ratio of -4.72, a P/E/G ratio of 1.53 and a beta of 1.40. Elanco Animal Health Incorporated has a 52-week low of $8.52 and a 52-week high of $18.80. The stock has a fifty day moving average of $14.40 and a 200 day moving average of $14.83. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.75 and a current ratio of 2.93.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. The business had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $1.15 billion. During the same quarter last year, the business posted $0.18 earnings per share. The company’s revenue for the quarter was up 12.0% on a year-over-year basis. On average, research analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Morgan Stanley lowered shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $17.00 to $15.00 in a research report on Thursday, September 19th. Piper Sandler dropped their price target on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a research note on Monday, July 1st. Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 price objective on shares of Elanco Animal Health in a research note on Thursday, September 19th. Finally, Barclays raised their price target on Elanco Animal Health from $21.00 to $22.00 and gave the stock an “overweight” rating in a report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Elanco Animal Health has a consensus rating of “Hold” and a consensus price target of $17.43.

Insider Buying and Selling at Elanco Animal Health

In other news, Director Michael J. Harrington purchased 3,500 shares of the stock in a transaction on Thursday, August 22nd. The shares were acquired at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the transaction, the director now directly owns 81,094 shares of the company’s stock, valued at approximately $1,204,245.90. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. In related news, Director Michael J. Harrington acquired 3,500 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The shares were purchased at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the acquisition, the director now owns 81,094 shares in the company, valued at approximately $1,204,245.90. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CEO Jeffrey N. Simmons acquired 100,000 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was bought at an average price of $13.01 per share, for a total transaction of $1,301,000.00. Following the acquisition, the chief executive officer now owns 145,000 shares of the company’s stock, valued at approximately $1,886,450. This trade represents a 200.00 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.57% of the company’s stock.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.